{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T10:15:05Z","timestamp":1786356905546,"version":"build-2736575974"},"reference-count":103,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.531790","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T08:42:47Z","timestamp":1601368967000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":55,"title":["Pathology of Hereditary Breast and Ovarian Cancer"],"prefix":"10.3389","volume":"10","author":[{"given":"Anjelica","family":"Hodgson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulisa","family":"Turashvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1126\/science.2270482","article-title":"Linkage of early-onset familial breast cancer to chromosome 17q21.","volume":"250","author":"Hall","year":"1990","journal-title":"Science."},{"key":"B2","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/ng1294-399","article-title":"Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families.","volume":"8","author":"Friedman","year":"1994","journal-title":"Nat Genet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1126\/science.7545954","article-title":"A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.","volume":"266","author":"Miki","year":"1994","journal-title":"Science."},{"key":"B4","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1126\/science.7939630","article-title":"BRCA1 mutations in primary breast and ovarian carcinomas.","volume":"266","author":"Futreal","year":"1994","journal-title":"Science."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1126\/science.8091231","article-title":"Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13.","volume":"265","author":"Wooster","year":"1994","journal-title":"Science."},{"key":"B6","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/378789a0","article-title":"Identification of the breast cancer susceptibility gene BRCA2.","volume":"378","author":"Wooster","year":"1995","journal-title":"Nature."},{"key":"B7","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.molcel.2012.07.029","article-title":"Playing the end game: DNA double-strand break repair pathway choice.","volume":"47","author":"Chapman","year":"2012","journal-title":"Mol Cell."},{"key":"B8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/s0092-8674(02)00615-3","article-title":"Cancer susceptibility and the functions of BRCA1 and BRCA2.","volume":"108","author":"Venkitaraman","year":"2002","journal-title":"Cell."},{"key":"B9","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1038\/ejhg.2016.93","article-title":"The biological effects and clinical implications of BRCA mutations: where do we go from here?","volume":"24","author":"Stoppa-Lyonnet","year":"2016","journal-title":"Eur J Hum Genet."},{"key":"B10","first-page":"265","article-title":"Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast cancer linkage consortium.","volume":"56","author":"Easton","year":"1995","journal-title":"Am J Hum Genet."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1056\/NEJM199705153362001","article-title":"The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.","volume":"336","author":"Struewing","year":"1997","journal-title":"N Engl J Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies.","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am J Hum Genet."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","article-title":"Meta-analysis of BRCA1 and BRCA2 penetrance.","volume":"25","author":"Chen","year":"2007","journal-title":"J Clin Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/jnci\/djt095","article-title":"Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.","volume":"105","author":"Mavaddat","year":"2013","journal-title":"J Natl Cancer Inst."},{"key":"B15","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa1400382","article-title":"Breast-cancer risk in families with mutations in PALB2.","volume":"371","author":"Antoniou","year":"2014","journal-title":"N Engl J Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1056\/nejme1405784","article-title":"PALB2 mutations and breast-cancer risk.","volume":"371","author":"Evans","year":"2014","journal-title":"N Engl J Med."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv214","article-title":"Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer.","volume":"107","author":"Ramus","year":"2015","journal-title":"J Natl Cancer Inst."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1200\/JCO.2015.61.2408","article-title":"Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population.","volume":"33","author":"Song","year":"2015","journal-title":"J Clin Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma.","volume":"474","year":"2011","journal-title":"Nature."},{"key":"B20","doi-asserted-by":"publisher","first-page":"18032","DOI":"10.1073\/pnas.1115052108","article-title":"Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.","volume":"108","author":"Walsh","year":"2011","journal-title":"Proc Natl Acad Sci USA."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-018-0935-9","article-title":"BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer.","volume":"20","author":"Weber-Lassalle","year":"2018","journal-title":"Breast Cancer Res."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11060740","article-title":"BARD1 is a low\/moderate breast cancer risk gene: evidence based on an association study of the Central European p.Q564X recurrent mutation.","volume":"11","author":"Suszynska","year":"2019","journal-title":"Cancers (Basel)."},{"key":"B23","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ccr.2007.01.010","article-title":"Ten genes for inherited breast cancer.","volume":"11","author":"Walsh","year":"2007","journal-title":"Cancer Cell."},{"key":"B24","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/ng.893","article-title":"Germline mutations in RAD51D confer susceptibility to ovarian cancer.","volume":"43","author":"Loveday","year":"2011","journal-title":"Nat Genet."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1200\/jco.19.00363","article-title":"Update on genetic testing in gynecologic cancer.","volume":"37","author":"Domchek","year":"2019","journal-title":"J Clin Oncol."},{"key":"B26","year":"2020","journal-title":"National Comprehensive Cancer Network Web Site."},{"key":"B27","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s10549-017-4198-4","article-title":"Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.","volume":"163","author":"Krammer","year":"2017","journal-title":"Breast Cancer Res Treat."},{"key":"B28","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1046\/j.1365-2559.1999.00584.x","article-title":"Prognostic comparison of three classifications for medullary carcinoma of the breast.","volume":"34","author":"Pedersen","year":"1999","journal-title":"Histopathology."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1002\/1097-0142(197710)40:4<1365::aid-cncr2820400402>3.0.co;2-n","article-title":"Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up.","volume":"40","author":"Ridolfi","year":"1977","journal-title":"Cancer."},{"key":"B30","article-title":"BRCA1\/2-associated hereditary breast and ovarian cancer syndrome.","year":"2019","journal-title":"Breast Tumours."},{"key":"B31","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours.","volume":"406","author":"Perou","year":"2000","journal-title":"Nature."},{"key":"B32","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1158\/1055-9965.EPI-11-0775","article-title":"Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the consortium of investigators of modifiers of BRCA1\/2 (CIMBA).","volume":"21","author":"Mavaddat","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1158\/1078-0432.ccr-1029-3","article-title":"Pathology of ovarian cancers in BRCA1 and BRCA2 carriers.","volume":"10","author":"Lakhani","year":"2004","journal-title":"Clin Cancer Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.1200\/jco.2010.33.6446","article-title":"Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women.","volume":"29","author":"Lee","year":"2011","journal-title":"J Clin Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s10549-017-4142-7","article-title":"Characteristics of BRCA1\/2 mutations carriers including large genomic rearrangements in high risk breast cancer patients.","volume":"163","author":"Park","year":"2017","journal-title":"Breast Cancer Res Treat."},{"key":"B36","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1159\/000101515","article-title":"BRCA1 germline mutation in a woman with metaplastic squamous cell breast cancer.","volume":"30","author":"Breuer","year":"2007","journal-title":"Onkologie."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0131409","article-title":"Clinicopathological features and prognosis of metaplastic breast carcinoma: experience of a major chinese cancer center.","volume":"10","author":"Zhang","year":"2015","journal-title":"PLoS One."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1200\/jco.2002.09.023","article-title":"The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.","volume":"20","author":"Lakhani","year":"2002","journal-title":"J Clin Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","article-title":"Inherited mutations in women with ovarian carcinoma.","volume":"2","author":"Norquist","year":"2016","journal-title":"JAMA Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/aog.0b013e31825f3576","article-title":"Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy.","author":"Schrader","year":"2012","journal-title":"Obstet Gynecol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/00004347-200210000-00011","article-title":"Histopathologic features of genetically determined ovarian cancer.","volume":"21","author":"Shaw","year":"2002","journal-title":"Int J Gynecol Pathol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/modpathol.2011.183","article-title":"Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma.","volume":"25","author":"Soslow","year":"2012","journal-title":"Mod Pathol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"6847","DOI":"10.1158\/1078-0432.ccr-08-1387","article-title":"Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology.","volume":"14","author":"Pal","year":"2008","journal-title":"Clin Cancer Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1126\/science.1088759","article-title":"New York Breast Cancer study group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.","volume":"302","author":"King","year":"2003","journal-title":"Science."},{"key":"B45","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/modpathol.2011.211","article-title":"BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma.","volume":"25","author":"McAlpine","year":"2012","journal-title":"Mod Pathol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1200\/jco.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation\u2013positive women with ovarian cancer: a report from the australian ovarian cancer study group.","volume":"30","author":"Alsop","year":"2012","journal-title":"J Clin Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1158\/1078-0432.ccr-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin Cancer Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/pap.0000000000000177","article-title":"Hereditary breast and ovarian cancer syndrome: moving beyond BRCA1 and BRCA2.","volume":"25","author":"Hoang","year":"2018","journal-title":"Adv Anat Pathol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1097\/pas.0b013e31825d9b8d","article-title":"Prediction of BRCA1 germ line mutation status in women with Ovarian cancer using morphology-based criteria: identification of a BRCA1 Ovarian cancer phenotype.","volume":"36","author":"Fujiwara","year":"2012","journal-title":"Am J Surg Pathol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/modpathol.2016.82","article-title":"Morphologic correlates of molecular alterations in extrauterine M\u00fcllerian carcinomas.","volume":"29","author":"Ritterhouse","year":"2016","journal-title":"Mod Pathol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1038\/modpathol.2013.237","article-title":"Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency.","volume":"27","author":"Reyes","year":"2014","journal-title":"Mod Pathol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1097\/pas.0000000000000556","article-title":"Invasion patterns of metastatic extrauterine high grade serous carcinoma with BRCA germline mutation and correlation with clinical outcomes.","volume":"40","author":"Hussein","year":"2016","journal-title":"Am J Surg Pathol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ygyno.2004.12.047","article-title":"Survival benefit for patients with advanced-stage transitional cell carcinomas vs. other subtypes of ovarian carcinoma after chemotherapy with platinum and paclitaxel.","volume":"97","author":"Kommoss","year":"2005","journal-title":"Gynecol Oncol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/pas.0b013e31826cabbd","article-title":"BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.","volume":"37","author":"Garg","year":"2013","journal-title":"Am J Surg Pathol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1093\/annonc\/mdu461","article-title":"The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer.","volume":"25","author":"Meisel","year":"2014","journal-title":"Ann Oncol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1349-7006.2000.tb00959.x","article-title":"Screening of BRCA1 mutation using immunohistochemical staining with C-terminal and N-terminal antibodies in familial ovarian cancers.","volume":"91","author":"Kashima","year":"2000","journal-title":"Jpn J Cancer Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1136\/jclinpath-2019-206276","article-title":"Immunohistochemistry for the detection of BRCA1 and BRCA2 proteins in patients with ovarian cancer: a systematic review.","volume":"73","author":"Teixeira","year":"2019","journal-title":"J Clin Pathol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/path.1000","article-title":"Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer.","volume":"195","author":"Piek","year":"2001","journal-title":"J Pathol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/path.5145","article-title":"Evidence for lineage continuity between early serous proliferations (ESPs) in the Fallopian tube and disseminated high-grade serous carcinomas.","volume":"246","author":"Soong","year":"2018","journal-title":"J Pathol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/01.pas.0000180854.28831.77","article-title":"The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome.","volume":"30","author":"Medeiros","year":"2006","journal-title":"Am J Surg Pathol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/pap.0b013e3181ecdee1","article-title":"A pathologist\u2019s road map to benign, precancerous, and malignant intraepithelial proliferations in the fallopian tube.","volume":"17","author":"Mehrad","year":"2010","journal-title":"Adv Anat Pathol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/pgp.0b013e31814b191f","article-title":"Serous carcinogenesis in the fallopian tube: a descriptive classification.","volume":"27","author":"Jarboe","year":"2008","journal-title":"Int J Gynecol Pathol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1097\/pas.0b013e3181ef7b16","article-title":"Are all pelvic (nonuterine) serous carcinomas of tubal origin?","volume":"34","author":"Przybycin","year":"2010","journal-title":"Am J Surg Pathol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/01.pas.0000213335.40358.47","article-title":"Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.","volume":"31","author":"Kindelberger","year":"2007","journal-title":"Am J Surg Pathol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1097\/00000478-200110000-00009","article-title":"Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status.","volume":"25","author":"Colgan","year":"2001","journal-title":"Am J Surg Pathol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/s1470-2045(11)70333-3","article-title":"Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project.","volume":"13","author":"Gilbert","year":"2012","journal-title":"Lancet Oncol."},{"key":"B67","year":"2020","journal-title":"Society of Gynecologic Oncology web site."},{"key":"B68","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10689-020-00166-5","article-title":"Perceptions of risk and reward in BRCA1 and BRCA2 mutation carriers choosing salpingectomy for ovarian cancer prevention.","volume":"19","author":"Ghezelayagh","year":"2020","journal-title":"Fam Cancer."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1097\/pas.0b013e31822f58bc","article-title":"Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study.","volume":"35","author":"Visvanathan","year":"2011","journal-title":"Am J Surg Pathol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/PGP.0b013e31823b8831","article-title":"Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma.","volume":"31","author":"Vang","year":"2012","journal-title":"Int J Gynecol Pathol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/path.3023","article-title":"TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma\u2013evidence supporting the clonal relationship of the two lesions.","volume":"226","author":"Kuhn","year":"2012","journal-title":"J Pathol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/path.2091","article-title":"A candidate precursor to serous carcinoma that originates in the distal fallopian tube.","volume":"211","author":"Lee","year":"2007","journal-title":"J Pathol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/modpathol.2016.238","article-title":"Serous tubal intraepithelial neoplasia: the concept and its application.","volume":"30","author":"Meserve","year":"2017","journal-title":"Mod Pathol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1038\/modpathol.2010.119","article-title":"High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression.","volume":"23","author":"Roh","year":"2010","journal-title":"Mod Pathol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/pas.0000000000000369","article-title":"Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma.","volume":"39","author":"Howitt","year":"2015","journal-title":"Am J Surg Pathol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.ygyno.2018.11.033","article-title":"The fallopian tube, \u201cprecursor escape\u201d and narrowing the knowledge gap to the origins of high-grade serous carcinoma.","volume":"152","author":"Soong","year":"2019","journal-title":"Gynecol Oncol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/pgp.0000000000000270","article-title":"Adopting a uniform approach to site assignment in tubo-ovarian high-grade serous carcinoma: the time has come.","volume":"35","author":"Singh","year":"2016","journal-title":"Int J Gynecol Pathol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1158\/1078-0432.ccr-18-1443","article-title":"Frequent homologous recombination deficiency in high-grade endometrial carcinomas.","volume":"25","author":"de Jonge","year":"2019","journal-title":"Clin Cancer Res."},{"key":"B79","doi-asserted-by":"publisher","first-page":"7517","DOI":"10.1158\/1078-0432.ccr-19-0848","article-title":"Germline BRCA-associated endometrial carcinoma is a distinct clinicopathologic entity.","volume":"25","author":"de Jonge","year":"2019","journal-title":"Clin Cancer Res."},{"key":"B80","article-title":"BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian.","volume":"7","author":"Friedenson","year":"2005","journal-title":"Medscape Gen Med."},{"key":"B81","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10689-011-9506-2","article-title":"Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations.","volume":"11","author":"Moran","year":"2012","journal-title":"Fam Cancer."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1111\/bjd.13626","article-title":"Skin cancer risk in BRCA1\/2 mutation carriers.","volume":"172","author":"Gumaste","year":"2015","journal-title":"Br J Dermatol."},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-018-0590-x","article-title":"Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors.","volume":"10","author":"Yang","year":"2018","journal-title":"Genome Med."},{"key":"B84","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s10549-017-4624-7","article-title":"Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1\/2 mutation-associated breast cancer.","volume":"168","author":"Telli","year":"2018","journal-title":"Breast Cancer Res Treat."},{"key":"B85","doi-asserted-by":"publisher","first-page":"6159","DOI":"10.1158\/1078-0432.ccr-10-1027","article-title":"A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer.","volume":"16","author":"Graeser","year":"2010","journal-title":"Clin Cancer Res."},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000004975","article-title":"Effect of BRCA germline mutations on breast cancer prognosis: a systematic review and meta-analysis.","volume":"95","author":"Baretta","year":"2016","journal-title":"Medicine (Baltimore)."},{"key":"B87","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.molcel.2006.01.036","article-title":"Condensin I interacts with the PARP-1-XRCC1 complex and functions in DNA single-strand break repair.","volume":"21","author":"Heale","year":"2006","journal-title":"Mol Cell."},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1186\/s40661-017-0055-8","article-title":"PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers.","volume":"4","author":"Sisay","year":"2017","journal-title":"Gynecol Oncol Res Pract."},{"key":"B89","doi-asserted-by":"publisher","first-page":"13587","DOI":"10.18632\/oncotarget.7277","article-title":"Association and prognostic significance of BRCA1\/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1\/PD-L1 in high grade serous ovarian cancer.","volume":"7","author":"Strickland","year":"2016","journal-title":"Oncotarget."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.18632\/oncotarget.6429","article-title":"Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.","volume":"7","author":"Darb-Esfahani","year":"2016","journal-title":"Oncotarget."},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0215381","article-title":"Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1\/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer.","volume":"14","author":"Wen","year":"2019","journal-title":"PLoS One."},{"key":"B92","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.2147\/cmar.s189627","article-title":"A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of BRCA-mutated breast cancer.","volume":"11","author":"Forbes","year":"2019","journal-title":"Cancer Manag Res."},{"key":"B93","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1177\/1758834017714993","article-title":"BRCA mutation in ovarian cancer: testing, implications and treatment considerations.","volume":"9","author":"Neff","year":"2017","journal-title":"Ther Adv Med Oncol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1002\/cncr.21536","article-title":"BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.","volume":"104","author":"Pal","year":"2005","journal-title":"Cancer."},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3422-2","article-title":"Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers.","volume":"17","author":"Grindedal","year":"2017","journal-title":"BMC Cancer."},{"key":"B96","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1097\/aog.0b013e3181a106d4","article-title":"ACOG Practice Bulletin No. 103: hereditary breast and ovarian cancer syndrome.","volume":"113","year":"2009","journal-title":"Obstet Gynecol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/gim.2014.147","article-title":"A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment.","volume":"17","author":"Hampel","year":"2015","journal-title":"Genet Med."},{"key":"B98","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ygyno.2014.09.009","article-title":"Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions.","volume":"136","author":"Lancaster","year":"2015","journal-title":"Gynecol Oncol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ygyno.2017.06.002","article-title":"Multi-disciplinary summit on genetics services for women with gynecologic cancers: a society of gynecologic oncology white paper.","volume":"146","author":"Randall","year":"2017","journal-title":"Gynecol Oncol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/jmedgenet-2018-105472","article-title":"Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap.","volume":"55","author":"McCuaig","year":"2018","journal-title":"J Med Genet."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1007\/s10897-017-0099-2","article-title":"Cancer genetic counseling and testing in an Era of rapid change.","volume":"26","author":"Hooker","year":"2017","journal-title":"J Genet Couns."},{"key":"B102","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s10689-015-9817-9","article-title":"Challenges to clinical utilization of hereditary cancer gene panel testing: perspectives from the front lines.","volume":"14","author":"Marcus","year":"2015","journal-title":"Fam Cancer."},{"key":"B103","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.pathol.2017.10.010","article-title":"Gynaecological neoplasms in common familial syndromes (Lynch and HBOC).","volume":"50","author":"Bartosch","year":"2018","journal-title":"Pathology (Phila)."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.531790\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T08:42:50Z","timestamp":1601368970000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.531790\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,29]]},"references-count":103,"alternative-id":["10.3389\/fonc.2020.531790"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.531790","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,29]]},"article-number":"531790"}}